Current Diabetes Reports

, Volume 3, Issue 1, pp 11–18 | Cite as

Prediabetes mellitus and its links to atherosclerosis

  • Daniel Kramer
  • Annaswamy Raji
  • Jorge Plutzky


Type 2 diabetes mellitus is a chronic insidious process contributing to an overwhelming amount of morbidity and mortality, much of which is related to atherosclerosis, which often accompanies and complicates the natural history of diabetes. Although considerable attention has focused on new insights into diabetic mechanisms and emerging treatments, perhaps one of the greatest opportunities for decreasing the toll of diabetes and its late-stage complications may be intervening earlier in the disease process. Such notions redirect attention toward the concept of prediabetes mellitus as a potentially discrete syndrome, which may be identifiable in clinical practice. This article seeks to offer support for this hypothesis by considering the data surrounding prediabetes mellitus, with particular attention on the mechanistic and clinical links to atherosclerosis.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356–359.PubMedCrossRefGoogle Scholar
  2. 2.
    Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.PubMedCrossRefGoogle Scholar
  3. 3.
    Haffner SM: Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors. Circulation 2001, 103:346–347.PubMedGoogle Scholar
  4. 4.
    Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570–2581.PubMedCrossRefGoogle Scholar
  5. 5.
    Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106:453–458. Excellent review that explores the relationship between insulin resistance, dyslipidemia, hypertension, hypercoagulability, and atherosclerosis toward understanding the link between insulin resistance and CVD.PubMedGoogle Scholar
  6. 6.
    Thompson WG: Early recognition and treatment of glucose abnormalities to prevent type 2 diabetes mellitus and coronary heart disease. Mayo Clin Proc 2001, 76:1137–1143.PubMedGoogle Scholar
  7. 7.
    Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486–2497.Google Scholar
  8. 8.
    Haffner SM, Mykkanen L, Festa A, et al.: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000, 101:975–980.PubMedGoogle Scholar
  9. 9.
    Reaven G: Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002, 106:286–288.PubMedCrossRefGoogle Scholar
  10. 10.
    Reaven GM: Pathophysiology of insulin resistance in human disease. Physiol Rev 1995, 75:473–486.PubMedGoogle Scholar
  11. 11.
    Haffner SM: Impaired glucose tolerance, insulin resistance and cardiovascular disease. Diabet Med 1997, 14(suppl 3):S12-S18.PubMedCrossRefGoogle Scholar
  12. 12.
    Maison P, Byrne CD, Hales CN, et al.: Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 2001, 24:1758–1763.PubMedCrossRefGoogle Scholar
  13. 13.
    McGill HC Jr, McMahan CA, Herderick EE, et al.: Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002, 105:2712–2718.PubMedCrossRefGoogle Scholar
  14. 14.
    Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171–176.PubMedGoogle Scholar
  15. 15.
    Kahn BB, Flier JS: Obesity and insulin resistance. J Clin Invest 2000, 106:473–481.PubMedGoogle Scholar
  16. 16.
    Beck-Nielsen H, Groop LC: Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994, 94:1714–1721.PubMedGoogle Scholar
  17. 17.
    Tominaga M, Eguchi H, Manaka H, et al.: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920–924.PubMedCrossRefGoogle Scholar
  18. 18.
    Despres JP, Lamarche B, Mauriege P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952–957.PubMedCrossRefGoogle Scholar
  19. 19.
    Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001, 285:2481–2485.PubMedCrossRefGoogle Scholar
  20. 20.
    Diercks GF, van Boven AJ, Hillege JL, et al.: The importance of microalbuminuria as a cardiovascular risk indicator: a review. Can J Cardiol 2002, 18:525–535.PubMedGoogle Scholar
  21. 21.
    Garg JP, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002, 7:35–43.PubMedCrossRefGoogle Scholar
  22. 22.
    Miyazaki H, Matsuoka H, Cooke JP, et al.: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999, 99:1141–1146.PubMedGoogle Scholar
  23. 23.
    Festa A, D’Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131–1137.PubMedCrossRefGoogle Scholar
  24. 24.
    Pradhan AD, Manson JE, Rifai N, et al.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327–334.PubMedCrossRefGoogle Scholar
  25. 25.
    Bjornholt JV, Erikssen G, Liestol K, et al.: Type 2 diabetes and maternal family history: an impact beyond slow glucose removal rate and fasting hyperglycemia in low-risk individuals? Results from 22.5 years of follow-up of healthy non-diabetic men. Diabetes Care 2000, 23:1255–1259.PubMedCrossRefGoogle Scholar
  26. 26.
    Harris MI: Epidemiological correlates of NIDDM in Hispanics, whites, and blacks in the U.S. population. Diabetes Care 1991, 14:639–648.PubMedCrossRefGoogle Scholar
  27. 27.
    Harris SB, Zinman B: Primary prevention of type 2 diabetes in high-risk populations. Diabetes Care 2000, 23:879–881.PubMedCrossRefGoogle Scholar
  28. 28.
    McClain MR, Srinivasan SR, Chen W, et al.: Risk of type 2 diabetes mellitus in young adults from a biracial community: the Bogalusa Heart Study. Prev Med 2000, 31:1–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Kim C, Newton KM, Knopp RH: Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002, 25:1862–1868.PubMedCrossRefGoogle Scholar
  30. 30.
    Norman RJ, Masters L, Milner CR, et al.: Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001, 16:1995–1998.PubMedCrossRefGoogle Scholar
  31. 31.
    Cavaghan MK, Ehrmann DA, Polonsky KS: Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000, 106:329–333.PubMedCrossRefGoogle Scholar
  32. 32.
    Bergenstal RM, Kendall DM, Franz MJ, Rubenstein A: Management of type 2 diabetes: a systemic approach to meeting the standards of self-management education, medical nutrition therapy, and exercise. In Endocrinology, edn 4. Edited by Degroot LJ, Jameson JL. St. Louis, MO: W.B. Saunders; 2001:820–822.Google Scholar
  33. 33.
    Wei M, Gaskill SP, Haffner SM, Stern MP: Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998, 21:1167–1172.PubMedCrossRefGoogle Scholar
  34. 34.
    Hu FB, Stampfer MJ, Haffner SM, et al.: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002, 25:1129–1134.PubMedCrossRefGoogle Scholar
  35. 35.
    Strong JP, Malcom GT, McMahan CA, et al.: Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999, 281:727–735.PubMedCrossRefGoogle Scholar
  36. 36.
    Toussaint JF, LaMuraglia GM, Southern JF, et al.: Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation 1996, 94:932–938.PubMedGoogle Scholar
  37. 37.
    Yuan C, Beach KW, Smith LH Jr, Hatsukami TS: Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. Circulation 1998, 98:2666–2671.PubMedGoogle Scholar
  38. 38.
    Hikita N, Tsuchihashi K, Nakata T, et al.: Involvement of glucose metabolism abnormalities and insulin resistance in atherosclerotic coronary artery disease: semiquantitative coronary angiography study [in Japanese]. J Cardiol 1998, 32:291–300.PubMedGoogle Scholar
  39. 39.
    Shinozaki K, Suzuki M, Ikebuchi M, et al.: Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care 1996, 19:1–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Weidinger F, Frick M, Alber HF, et al.: Association of wall thickness of the brachial artery measured with high-resolution ultrasound with risk factors and coronary artery disease. Am J Cardiol 2002, 89:1025–1029.PubMedCrossRefGoogle Scholar
  41. 41.
    Teragawa H, Kato M, Kurokawa J, et al.: Usefulness of flow-mediated dilation of the brachial artery and/or the intimamedia thickness of the carotid artery in predicting coronary narrowing in patients suspected of having coronary artery disease. Am J Cardiol 2001, 88:1147–1151.PubMedCrossRefGoogle Scholar
  42. 42.
    Urbina EM, Brinton TJ, Elkasabany A, Berenson GS: Brachial artery distensibility and relation to cardiovascular risk factors in healthy young adults (The Bogalusa Heart Study). Am J Cardiol 2002, 89:946–951.PubMedCrossRefGoogle Scholar
  43. 43.
    Haffner SM, Gonzales C, Valdez RA, et al.: Is microalbuminuria part of the prediabetic state? The Mexico City Diabetes Study. Diabetologia 1993, 36:1002–1006.PubMedCrossRefGoogle Scholar
  44. 44.
    Gerstein HC, Mann JF, Pogue J, et al.: Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care 2000, 23(suppl 2):B35-B39.PubMedGoogle Scholar
  45. 45.
    Turner RC, Millns H, Neil HA, et al.: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823–828.PubMedGoogle Scholar
  46. 46.
    MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial [no authors listed]. Lancet 2002, 360:7–22.Google Scholar
  47. 47.
    Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135–1143. Excellent overview of inflammatory mechanisms in atherosclerosis.PubMedCrossRefGoogle Scholar
  48. 48.
    Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115–126.PubMedCrossRefGoogle Scholar
  49. 49.
    Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403. A landmark diabetes prevention trial that highlights the role of lifestyle modification in the prevention of T2DM.PubMedCrossRefGoogle Scholar
  50. 50.
    Chiasson JL, Josse RG, Gomis R, et al.: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072–2077.PubMedCrossRefGoogle Scholar
  51. 51.
    Wing RR, Venditti E, Jakicic JM, et al.: Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care 1998, 21:350–359.PubMedCrossRefGoogle Scholar
  52. 52.
    Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343–1350.PubMedCrossRefGoogle Scholar
  53. 53.
    Chakravarthy MV, Joyner MJ, Booth FW: An obligation for primary care physicians to prescribe physical activity to sedentary patients to reduce the risk of chronic health conditions. Mayo Clin Proc 2002, 77:165–173.PubMedCrossRefGoogle Scholar
  54. 54.
    Ludwig DSZ: The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 2002, 287:2414–2423.PubMedCrossRefGoogle Scholar
  55. 55.
    Westman EC, Yancy WS, Edman JS, et al.: Effect of 6-month adherence to a very low carbohydrate diet program. Am J Med 2002, 113:30–36.PubMedCrossRefGoogle Scholar
  56. 56.
    U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group [no authors listed]. Diabetes 1995, 44:1249–1258.Google Scholar
  57. 57.
    Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in highrisk Hispanic women. Diabetes 2002, 51:2796–2803.PubMedCrossRefGoogle Scholar
  58. 58.
    Azen SP, Peters RK, Berkowitz K, et al.: TRIPOD (Troglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998, 19:217–231.PubMedCrossRefGoogle Scholar
  59. 59.
    Kreisberg RA, Oberman A: Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab 2002, 87:423–437.PubMedCrossRefGoogle Scholar
  60. 60.
    Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/ CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286:64–70.PubMedCrossRefGoogle Scholar
  61. 61.
    Ridker PM, Rifai N, Pfeffer MA, et al.: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investisssgators. Circulation 1999, 100:230–235.PubMedGoogle Scholar
  62. 62.
    Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2003

Authors and Affiliations

  • Daniel Kramer
  • Annaswamy Raji
  • Jorge Plutzky
    • 1
  1. 1.The Vascular Disease Prevention Program, Cardiovascular Division, Department of MedicineBrigham and Women’s HospitalBostonUSA

Personalised recommendations